Patent ID: 9279006
Filing Date: 2016-03-08
CPC Classification: A61K,A61P,C07K,C12N,Y02A

Claim Text:
1. A method of protecting malaria-naïve human subjects against productive malaria infection due to Plasmodium falciparum comprising: (i) selecting malaria-naïve human subjects and (ii) administering to said malaria-naïve human subjects a formulation comprising: (a) an immunogenic amount of the RTS,S malaria vaccine comprising the RTS hybrid protein and the S protein of hepatitis B virus (HBsAg) in the form of mixed particles, wherein the RTS hybrid protein comprises substantially all the C-terminal portion of the circumsporozoite (CS) protein of (b) adjuvant B comprising 3D-MPL and QS21, the QS21 quenched in cholesterol-containing liposomes, thereby protecting the malaria-naïve human subjects against the productive malaria infection due to Plasmodium falciparum.